Nuvig Therapeutics has closed a $161 million Series B financing and announced plans to progress to Phase II development with its immunomodulator for inflammatory autoimmune diseases.  The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners.  There was also participation from new investors, B Capital, Leaps […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!